Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2014 Jun 10;23(9):1873–1883. doi: 10.1158/1055-9965.EPI-14-0263

Table 1.

Study Variables by Race/Ethnicity

Variable Patients AA1 HW1 NHW1 Other
N % N % N % N % N % P2
Study Population 159 100 29 18.2 96 60.4 29 18.2 5 3.1
Age: Mean (SD) 56.3 (9.3) 55.1 (7.4) 57.2 (9.4) 55.5 (10.5) 50.2 (9.2) 0.30
BMI (kg/m2)
  <25 47 29.6 4 13.8 24 25.0 15 51.7 4 80.0 0.003
  25 – 29.99 51 32.1 7 24.1 37 38.5 6 20.7 1 20.0
  ≥30 61 38.4 18 62.1 35 36.5 8 27.6 0 0
Clinical stage
  0 33 20.8 5 17.2 22 22.9 4 13.8 2 40.0 0.23
  IA–B 79 49.7 11 37.9 51 53.1 16 55.2 1 20.0
  IIA–IIIC 47 29.6 13 44.8 23 24.0 9 31.0 2 40.0
Smoking History
  Never 108 67.9 18 62.1 8 70.8 18 62.1 4 80.0 0.53
  Ever 51 32.1 11 37.9 28 29.2 11 37.9 1 20.0
Smoking Status
  Never 108 67.9 18 62.1 68 70.8 18 62.1 4 80.0 0.30
  Former 45 28.3 8 27.6 26 27.1 10 34.5 1 20.0
  Current 6 3.8 3 10.3 2 2.1 1 3.4 0 0
Week 3 EASR grade
  0 25 15.8 5 17.9 16 16.7 2 6.9 2 40.0 0.10
  1 125 79.1 20 71.4 78 81.3 24 82.8 3 60.0
  2 8 5.1 3 10.7 2 2.1 3 10.3 0 0
Week 6 EASR grade
  0 2 1.3 1 3.4 1 1.0 0 0 0 0 0.173
  1 77 48.4 12 41.4 46 47.9 15 51.7 4 80.0
  2 73 45.9 12 41.4 47 49.0 13 44.8 1 20.0
  3 7 4.4 4 13.8 2 2.1 1 3.4 0 0
Pre-RT CRP (mg/L)
  < 10 145 91.2 24 82.8 90 93.8 27 93.1 4 80.0 0.25
  ≥ 10 14 8.8 5 17.2 6 6.3 2 6.9 1 20.0
  < 2 58 36.5 8 27.6 36 37.5 13 44.8 1 20.0 0.39
  ≥ 2 101 63.5 21 72.4 60 62.5 16 55.2 4 80.0
Post-RT CRP (mg/L)
  < 10 141 88.7 23 79.3 87 90.6 27 93.1 4 80.0 0.20
  ≥ 10 18 11.3 6 20.7 9 9.4 2 6.9 1 20.0
  < 2 56 35.2 7 24.1 34 35.4 13 44.8 2 40.0 0.25
  ≥ 2 103 64.8 22 75.9 62 64.6 16 55.2 3 60.0
Post-RT- pre-RT CRP(mg/L)
  <0 71 44.7 12 41.4 41 42.7 14 48.3 4 80.0 0.36
  0 10 6.3 0 0 8 8.3 2 6.9 0 0
  >0 and <1 44 27.7 7 24.1 30 31.3 6 20.7 1 20.0
  ≥1 34 21.4 10 34.5 17 17.7 7 24.1 0 0
# of Comorbidities4
  0 65 40.9 6 20.7 42 43.8 14 48.3 3 60.0 0.13
  1 56 35.2 12 41.4 35 36.5 9 31.0 0 0
  2 28 17.6 8 27.6 15 15.6 3 10.3 2 40.0
  ≥3 10 6.3 3 10.3 4 4.2 3 10.3 0 0
Total RT dose (Gy)5
  <60 33 20.8 5 17.2 18 18.8 9 31.0 1 20.0 0.31
  60 108 67.9 20 69.0 69 71.9 15 51.7 4 80.0
  >60 18 11.3 4 13.8 9 9.4 5 17.2 0 0
Breast volume (CC)
  Mean (SD) 958 (509) 1358 (647) 905 (437) 808 (408) 587 (251) <0.0001
  Median 864 1357 831 774 593
  Below Median (<864) 77 49.7 8 28.6 49 52.7 16 55.2 4 80.0 0.06
  Above median (≥ 864) 78 50.3 20 71.4 44 47.3 13 44.8 1 20.0
1

AA, Black or African American; HW, Hispanic Whites; NHW, Non-Hispanic Whites.

2

Chi-square or Fisher’s exact tests excluding the other race category and missing.

3

Combined early adverse skin reaction (EASR) grades 0 and 1.

4

Sum of 11 comorbidity conditions: diabetes, hypertension, heart disease, lung disease, thyroid condition, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, and other.

5

Sum of total breast and boost radiation doses; the ranged was between 50 to 66.4 Gy except for one patient at 38.5 Gy.